Adage Capital Partners’s Sage Therapeutics SAGE Stock Holding History

Adage Capital Partners’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-442,000	Closed	-$38.2M	–	1016
2020 Q4	$38.2M	Sell	442,000 -500,000	-53%	-$36.9M	0.08%	261
2020 Q3	$57.6M	Buy	+942,000	New	+$47.7M	0.14%	157
2020 Q1	–	Sell	-50,000	Closed	-$3.61M	–	784
2019 Q4	$3.61M	Buy	50,000 +30,000	+150%	+$3.69M	0.01%	637
2019 Q3	$2.81M	Hold	20,000	–	–	0.01%	656
2019 Q2	$3.66M	Hold	20,000	–	–	0.01%	640
2019 Q1	$3.18M	Buy	+20,000	New	+$2.9M	0.01%	634
2018 Q1	–	Sell	-133,000	Closed	-$21.9M	–	760
2017 Q4	$21.9M	Buy	+133,000	New	+$12.9M	0.05%	388

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Adage Capital Partners's SAGE Position: Q1 2021 in Review

Adage Capital Partners sold out of Sage Therapeutics (SAGE) in Q1 2021, closing a stake of 442,000 shares — an estimated $38.2M sold.

Adage Capital Partners first reported a position in SAGE in Q4 2017 and held it in 7 quarters. The position peaked at $57.6M in Q3 2020. 262 funds tracked by Wall St. Rank hold SAGE as of Q1 2021.

Adage Capital Partners reported no remaining Sage Therapeutics position as of Q1 2021 after selling out during the quarter.
Adage Capital Partners sold 442,000 Sage Therapeutics shares in Q1 2021, an estimated $38.2M.
Adage Capital Partners first reported a position in Sage Therapeutics in Q4 2017 and held it in 7 quarters.
Adage Capital Partners's Sage Therapeutics position peaked at $57.6M in Q3 2020.
262 funds tracked by Wall St. Rank held Sage Therapeutics as of Q1 2021.

Based on Adage Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.